08:37 AM EDT, 06/05/2024 (MT Newswires) -- Adicet Bio ( ACET ) said Wednesday that the US Food and Drug Administration has granted fast track designation to ADI-001 to potentially treat relapsed/refractory class III or class IV lupus nephritis.

The company said it will start the early-stage clinical trial in lupus nephritis later this month.

Shares of Adicet were up 17% in recent Wednesday premarket activity.

Price: 1.5500, Change: +0.19, Percent Change: +13.97